Literature DB >> 24569448

Current approaches to the treatment of metastatic brain tumours.

Taofeek K Owonikoko1, Jack Arbiser2, Amelia Zelnak1, Hui-Kuo G Shu3, Hyunsuk Shim3, Adam M Robin4, Steven N Kalkanis4, Timothy G Whitsett5, Bodour Salhia6, Nhan L Tran5, Timothy Ryken7, Michael K Moore8, Kathleen M Egan9, Jeffrey J Olson8.   

Abstract

Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency and are an important complication in the overall management of many cancers. Importantly, advances are being made in understanding the molecular biology underlying the initial development and eventual proliferation of brain metastases. Surgery and radiation remain the cornerstones of the therapy for symptomatic lesions; however, image-based guidance is improving surgical technique to maximize the preservation of normal tissue, while more sophisticated approaches to radiation therapy are being used to minimize the long-standing concerns over the toxicity of whole-brain radiation protocols used in the past. Furthermore, the burgeoning knowledge of tumour biology has facilitated the entry of systemically administered therapies into the clinic. Responses to these targeted interventions have ranged from substantial toxicity with no control of disease to periods of useful tumour control with no decrement in performance status of the treated individual. This experience enables recognition of the limits of targeted therapy, but has also informed methods to optimize this approach. This Review focuses on the clinically relevant molecular biology of brain metastases, and summarizes the current applications of these data to imaging, surgery, radiation therapy, cytotoxic chemotherapy and targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569448      PMCID: PMC4041037          DOI: 10.1038/nrclinonc.2014.25

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  209 in total

1.  Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Authors:  Yoshiaki Kinoshita; Yasutaka Koga; Atsuhiko Sakamoto; Kouko Hidaka
Journal:  BMJ Case Rep       Date:  2013-09-10

Review 2.  Neuroimaging in neuro-oncology.

Authors:  Soonmee Cha
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 3.  Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Authors:  Monique P Curran
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

4.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

Authors:  B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-04-07       Impact factor: 32.976

5.  HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.

Authors:  Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

6.  Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

7.  Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Authors:  Mihaela Lorger; Joseph S Krueger; Melissa O'Neal; Karin Staflin; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

8.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

Review 9.  Molecular interactions in the development of brain metastases.

Authors:  Nina Martinez; Adrienne Boire; Lisa M Deangelis
Journal:  Int J Mol Sci       Date:  2013-08-20       Impact factor: 5.923

10.  Selective permeabilization of the blood-brain barrier at sites of metastasis.

Authors:  John J Connell; Grégoire Chatain; Bart Cornelissen; Katherine A Vallis; Alastair Hamilton; Len Seymour; Daniel C Anthony; Nicola R Sibson
Journal:  J Natl Cancer Inst       Date:  2013-10-09       Impact factor: 13.506

View more
  101 in total

1.  Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Authors:  Jin Kyung Rho; In Yong Lee; Yun Jung Choi; Chang-Min Choi; Jae-Young Hur; Jong Sung Koh; Jaekyoo Lee; Byung-Chul Suh; Ho-Juhn Song; Paresh Salgaonkar; Jungmi Lee; Jaesang Lee; Dong Sik Jung; Sang-Yeob Kim; Dong-Cheol Woo; In-Jeoung Baek; Joo-Yong Lee; Chang Hoon Ha; Young Hoon Sung; Jeong Kon Kim; Woo Sung Kim; Joon Seon Song; Cheol Hyeon Kim; Trever G Bivona; Jae Cheol Lee
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

Review 2.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

Review 3.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.

Authors:  Hila Doron; Tobias Pukrop; Neta Erez
Journal:  Cancer Res       Date:  2019-01-24       Impact factor: 12.701

4.  VEGF-B-Neuropilin-1 signaling is spatiotemporally indispensable for vascular and neuronal development in zebrafish.

Authors:  Lasse D Jensen; Masaki Nakamura; Lars Bräutigam; Xuri Li; Yizhi Liu; Nilesh J Samani; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

5.  Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.

Authors:  Fabio Y Moraes; Jeff Winter; Eshetu G Atenafu; Archya Dasgupta; Hamid Raziee; Catherine Coolens; Barbara-Ann Millar; Normand Laperriere; Maitry Patel; Mark Bernstein; Paul Kongkham; Gelareh Zadeh; Tatiana Conrad; Caroline Chung; Alejandro Berlin; David B Shultz
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

6.  [Chemotherapy of brain tumors in aduts].

Authors:  P Roth; M Weller
Journal:  Nervenarzt       Date:  2015-04       Impact factor: 1.214

Review 7.  Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours.

Authors:  Milan T Makale; Carrie R McDonald; Jona A Hattangadi-Gluth; Santosh Kesari
Journal:  Nat Rev Neurol       Date:  2016-12-16       Impact factor: 42.937

8.  Historical perspectives on the biology of brain metastasis.

Authors:  J Dawn Waters; Reid Hoshide; Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2017-09-06       Impact factor: 5.150

9.  The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation.

Authors:  Shih-Fan Lai; Yu-Hsuan Chen; Tony Hsiang-Kuang Liang; Che-Yu Hsu; Huang-Chun Lien; Yen-Sen Lu; Chiun-Sheng Huang; Sung-Hsin Kuo
Journal:  J Neurooncol       Date:  2018-03-20       Impact factor: 4.130

10.  Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Authors:  Maria Sambade; Allison Deal; Allison Schorzman; J Christopher Luft; Charles Bowerman; Kevin Chu; Olga Karginova; Amanda Van Swearingen; William Zamboni; Joseph DeSimone; Carey K Anders
Journal:  Nanomedicine (Lond)       Date:  2016-07-26       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.